Reservoir Minerals Has Many Options to Enhance Value
Source: Adrian Day  (3/24/16)
Reservoir Minerals Inc. (RMC:TSX.V) has moved up sharply this month—over 50%—after Lundin Mining Corp. (LUX:TSX) made an offer to buy part of Freeport-McMoRan Copper & Gold Inc.'s (FCX:NYSE) interest in its joint venture with Reservoir. But it remains a strong buy. More >

How to Trade Sarepta Therapeutics Ahead of ADCOM: Chen Lin
Source: Chen Lin, What Is Chen Buying? What Is Chen Selling?  (3/24/16)
Sarepta Therapeutics Inc. (SRPT:NASDAQ) is scheduled to have its FDA Advisory Committee Meeting (ADCOM) to review eteplirsen as a treatment for Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping on April 25, a little over a month from now. According to newsletter writer Chen Lin, this is a huge binary event for the company. In this article, Lin lays out his investment thesis on the stock ahead of the meeting, and his hopes for eteplirsen's approval. More >

Nobilis Health Doubles Down, Offering Organic Growth and Aggressive Acquisitions: Kolin Ozonian
Source: George S. Mack of The Life Sciences Report  (3/23/16)
Businesses can grow in two ways—internally and externally. Nobilis Health Corp. has a voracious appetite for both. The company is a development and management firm that acquires private outpatient surgical centers—in short, it's a business model built on efficiencies. Nobilis scans the market for clinics that can be acquired and scaled up using sophisticated direct marketing approaches. In this interview with The Life Sciences Report, Nobilis' mergers-and-acquisitions specialist Kolin Ozonian talks about the business model and tells investors how he and the Nobilis team plan to aggressively grow the company. More >

Cellceutix Pipeline Continues to Hit Milestone After Milestone
Source: Staff of The Life Sciences Report  (3/23/16)
Cellceutix Corp. (CTIX:OTCMKTS), a small-cap biotech company focused on developing novel compounds for a range of applications, has released a flurry of announcements over the past five weeks as several of its pipeline drugs cleared regulatory hurdles and readied for their next milestones. The series of press releases on three different Cellceutix experimental drugs put a charge in the stock, sending it upward in a matter of a few days by more than 57% to a high of $1.81/share on Tuesday, March 21. More >

Ominous Response to Brussels Torpedoes Precious Metals Rally…
Source: Michael Ballanger  (3/23/16)
Michael Ballanger discusses the effect of events in Brussels on precious metals. More >

Sumitomo's Quest for Gold Starts with Viscount Mining
Source: Gwen Preston, Resource Maven  (3/21/16)
Japanese giant Sumitomo Corporation is on a quest for gold. Its only exploration-level joint venture is with Viscount Mining. Resource Maven Gwen Preston explores the Viscount proposition, including the historic potential of its Cherry Creek, Nevada, land package and its potential to produce Carlin-type gold. More >

Anchored in the Misery of the Last Bear Market…
Source: Michael J. Ballanger  (3/18/16)
Michael Ballanger dissects Friday's Commitment of Traders Report and whether it indicates bullish or bearish movements. More >

Torchlight Energy: Unlocking Value into the Oil Bear
Source: Dallas Salazar of Capgainr.com  (3/17/16)
The low price of oil has meant that a lot of companies are going broke, but not so with Torchlight Energy. A subsidiary of D.R. Horton is spending $50 million, fully funding the development of Torchlight's Orogrande project over the next 24 months. More >

Towels Thrown In, White Flags raised? Not Yet, but Close…
Source: Michael Ballanger  (3/17/16)
In the wake of what Michael Ballanger calls a "non-decision by the U.S. central banksters," the precious metals expert remains cautious and watchful. In this article, Ballanger offers his take on what the recent Fed decision on interest rates means for investors and the markets, and the circumstances that might force him to toss in the towel. More >

From Acorns Mighty Biotech Trees Can Grow: Laidlaw's Jim Molloy
Source: George S. Mack of The Life Sciences Report  (3/16/16)
After a devastating start to 2016, biotech stocks have snapped back. Laidlaw & Co. analyst Jim Molloy likes the resurgence he's seeing in biotechnology share prices, but cautions that confirmation of a recovery will require cash-laden drug developers to begin acquiring smaller biotechs trading at depressed market valuations. In the meantime, Molloy says, individual and small institutional investors can still buy growth stories at bargain prices. In this interview with The Life Sciences Report, Molloy mentions three names with near-term catalysts that, with good data, can bring a needed lift to biotech portfolios. More >

'Et tu, Brute?': It Took a Month for the Commercials to Pull the Trigger…
Source: Michael Ballanger  (3/15/16)
When precious metals expert Michael Ballanger looks at the current state of the precious metals markets, he is reminded of that scene from Shakespeare's Julius Caesar when the wounded emperor looks up into his friend Brutus' eyes and utters the immortal words, "Et tu, Brute?" More >

Zero-Hour for the Precious Metals…
Source: Michael J. Ballanger  (3/14/16)
Just as the world was breathing a massive and collective sigh of relief that a new bull market in gold and silver had arrived with all the pomp and pageantry of a Royal Wedding, the Barbarians climbed the walls and are now very close to razing the palace, says precious metals expert Michael Ballanger. More >

Near-Term Gold Forecast: The Thrill of Victory and the Agony of Indecision. . .
Source: Michael Ballanger   (3/11/16)
Man-oh-man, the heat I am taking over my recent "Caution" stance on the near-term outlook for gold and silver is now verging on the theatre of the absurd, says precious metals expert Michael Ballanger. More >

Hedge Fund Chief Warren Irwin's Blockbuster Uranium Call and His Best Metal and Oil Plays
Source: Gordon Holmes of The Gold Report  (3/10/16)
The event-driven hedge fund Rosseau LP has beat its benchmark by over 50% since inception in 1998, and its founder and CIO Warren Irwin says it does so by going deep, looking at very specific events or situations that are special within industry sectors. Irwin made his name by shorting Bre-X some 20 years ago and hasn't looked back. In this interview with The Gold Report, Irwin gives us a peek into Rosseau's portfolio, discussing opportunities that he is excited about in metals, uranium and oil. More >

Seven Biotech Names on the Upswing: 2016 Small-Cap Biotech Watchlist Update
Source: Tracy Salcedo of The Life Sciences Report  (3/9/16)
Biotech stocks—and the stock market in general—took a dive at the beginning of 2016, headed down on macroeconomic factors such as financial instability in China. The Life Sciences Report's 2016 Small-Cap Biotech Watchlist was not immune to that movement, heading into negative territory almost from the moment the selected companies were introduced. But as the market has shown signs of rebounding, so too has the Watchlist.
More >

VSA Capital's Paul Renken: Gold and Lithium Companies that Are Sizzling Hot
Source: Brian Sylvester of The Gold Report  (3/7/16)
There wasn't much sizzle in the gold equities space in recent years, but that has recently changed. Paul Renken, chief geologist and analyst with London-based VSA Capital, says the recent uptick in the gold price—which he says should stay near current levels for a while—will boost the margins of already profitable gold producers. Renken is even more bullish on lithium, while remaining optimistic about uranium. In this interview with The Gold Report, Renken provides the gold, lithium and uranium names with sizzle. More >

Kiss the Bear Goodbye (But Wear a Helmet). . .
Source: Michael J. Ballanger for The Gold Report  (3/4/16)
Friday's morning action in gold has been at once both terrific and frothy, wonderful and scary, and redemptive and soothing, says precious metals expert Michael Ballanger. More >

Embrace Low-Cap Biotech for High Gains: Eden Rahim of Next Edge Capital
Source: George S. Mack of The Life Sciences Report  (3/2/16)
Eden Rahim of Toronto-based Next Edge Capital has had his share of multibagger and grand-slam successes, and is one of the few mutual fund managers who feels comfortable investing in micro-cap biotech names side-by-side with billion-dollar biotech stocks. In this interview with The Life Sciences Report, Rahim describes a group of micro-, small- and mid-cap biotech names possessing powerful growth drivers that could perform even when the overall market is not so hot. More >

Behold the New Golden Bandwagon. . .
Source: Michael J. Ballanger for The Gold Report  (3/2/16)
Precious metals expert Michael Ballanger says we are actually back in a bona fide, brand-spanking-new bull market in gold and the gold miners. More >

Faulty Barometer
Source: Joe McAlinden for The Gold Report  (3/2/16)
A cacophony of a recession chatter is filling the airwaves. Some experts are already declaring we are in one while others are raising warning flags. Their message has not been lost on the masses: Google searches for the word "recession" have risen to the highest level since 2012. Interestingly, many commentators cite the 20% decline in global stock prices as the warning signal, if not the cause. But veteran investor Joe McAlinden believes the U.S. economy will continue to expand in the year ahead. More >

Commodities: Early Signs of Bottoming
Source: Leon Tuey for The Gold Report  (3/2/16)
Veteran investor Leon Tuey says he believes, contrary to conventional wisdom, the economy is not heading into recession and commodities are showing early signs of bottoming. More >

Negative Outside Reversal Day: Beware the Ides of March
Source: Michael J. Ballanger for The Gold Report  (3/1/16)
Precious metals expert Michael Ballanger believes we are in the very early stages of an absolutely breath-taking bull market in mining stocks and the precious metals, but like the famous Aesopian fable, sometimes it's the tortoise that wins the race by simply plodding along and exercising patience and a tad of caution. More >

Graphite: What iPhones, NASCAR and Tesla Have in Common
Source: Special to The Gold Report  (2/29/16)
Focus Graphite CEO and Director Gary Economo says the tipping point is coming for natural flake mining developers—even during a depressed commodities cycle. This optimistic view is based on the urgent necessity of manufacturers today to source those critical materials and technologies needed to meet globally mandated CleanTech targets in advance of a 2020 deadline. Focus, says Economo, is on strategic trajectory to capitalize on global change with his company's high-purity graphite deposit, Lac Knife in Quebec. More >

Patiently Climbing Aboard the New Golden Bull
Source: Michael J. Ballanger for The Gold Report  (2/29/16)
Precious metals expert Michael Ballanger has done his research and believes the long-term and intermediate-term status of the gold market and its associated gold miners is unequivocally bullish. In this article for The Gold Report, he lays out his case, explaining that every indicator he has used since the late 1970s is kicking into gear. More >

0

Why Brent Cook and Joe Mazumdar Are Doubling Down on the Exploration and the Insights
Source: JT Long of The Gold Report  (2/25/16)
Now that Exploration Insights founder Brent Cook is starting to see the bright side of the mining equity cycle, he brought in former Canaccord Genuity Analyst Joe Mazumdar to cover developers and producers at the newsletter. In this interview with The Gold Report, the pair share observations from their recent travels and a short list of companies they are compiling to take advantage of a possible upswing in gold in all currencies. More >